All the highly speculative froth, and less-speculative-but-still-very-expensive secular growth stocks getting carted off a positive discount factor.
There’s a fair amount of nexus-between-unprofitable-health-tech-and-finance below.
And a slightly odd grab bag of stocks for those positive on a day like today, with offshore dollar earners (that do well when the AUD goes down) and rate sensitives (+ve rates beta) making up most of the list, alongside some quality staples.
Our direct equity portfolios are doing quite well today, relative to the benchmark, as a) we have a pretty low beta (~.90x market) b) we are long the rate sensitives c) we are defensively positioned with almost no exposure to tech and consumer discretionary.
Of that list we have Amcor, Suncorp, TPG, Brambles, ANZ, and had just sold Ramsay due to the takeover bid.
Anyway, days like today can feel scary or deeply unpleasant for clients, and the good news is that whilst we cannot predict the timing of days like today, we can position prudently ahead of time for them, and so both the multi-asset funds, and the direct equity portfolios (for which most of the above commentary applies) should hold in good stead.
Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Please note that past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.